UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_______________

FORM 8-K

CURRENT REPORT


Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 30, 2004
_______________

Targeted Genetics Corporation
(Exact name of registrant as specified in charter)

Washington

0-23930

91-1549568




(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)

1100 Olive Way, Suite 100
Seattle, Washington
98101


(Address of principal executive offices and Zip Code)

(206) 623-7612

(Registrant's telephone number, including area code)
 
 
Not Applicable
(Former name or former address, if changed since last report)





Item 5.         Other Events

        On February 2, 2004, Targeted Genetics Corporation announced a public offering of 10,854,247 shares of its common stock to institutional investors at a price of $2.35 per share, for gross proceeds of $25,507,504. The shares were offered under Targeted Genetics’ shelf registration statement on Form S-3 (File 333-107822), as amended.

        Targeted Genetics expects to receive net proceeds from the financing of approximately $23.8 million after deducting placement agent fees and estimated costs associated with the offering. SG Cowen Securities Corporation, or SG Cowen, and Roth Capital Partners, LLC, or Roth, served as placement agents for the transaction.

        Copies of the Placement Agent Agreement between Targeted Genetics and Roth, dated as of January 30, 2004 and the form of the Subscription Agreement among Targeted Genetics and each institutional purchaser, and the press release related to the offering are attached as Exhibits 1.1, 10.1 and 99.1 to this current report and are incorporated herein by reference.

Item 7.          Financial Statements and Exhibits

(c)  

Exhibits.


1.1  

Placement Agent Agreement


10.1  

Form of Subscription Agreement


99.1  

Press Release of Targeted Genetics Corporation dated February 2, 2004







SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


Targeted Genetics Corporation
 
Date: February 3, 2004 By:   /s/ Todd E. Simpson                          
Todd E. Simpson
Vice President, Finance and Administration, Chief Financial Officer, Secretary and Treasurer




EXHIBIT INDEX

Exhibit  
Number

       Description


1.1  

Placement Agent Agreement


10.1  

Form of Subscription Agreement


99.1  

Press Release of Targeted Genetics Corporation dated February 2, 2004